{"title":"Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.","authors":"Shivani Sood, Gurpreet Kaur Bhatia, Prachi Seth, Pawan Kumar, Jagjit Kaur, Vidisha Gupta, Sandeep Punia, Hardeep Singh Tuli","doi":"10.1007/s40495-021-00253-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>The widespread respiratory disease of virus known as severe acute respiratory syndrome-coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world.</p><p><strong>Recent findings: </strong>The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2.</p><p><strong>Summary: </strong>The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019<b>.</b></p>","PeriodicalId":11139,"journal":{"name":"Current Pharmacology Reports","volume":"7 2","pages":"49-54"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40495-021-00253-w","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40495-021-00253-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 13
Abstract
Purpose of review: The widespread respiratory disease of virus known as severe acute respiratory syndrome-coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world.
Recent findings: The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2.
Summary: The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019.
期刊介绍：
Current Pharmacology Reports will: publish cutting-edge reviews on subjects pertinent to all aspects of pharmacology, including drug discovery and development.provide incisive, insightful, and balanced contributions from international leading experts.interest a wide readership of basic scientists and translational investigators in academia and in industry. The Current Pharmacology Reports journal accomplishes its goal by appointing international authorities to serve as Section Editors in key subject areas, such as: epigenetics and epigenomics, chemoinformatics and rational drug design and target discovery, drug delivery and biomaterial, pharmacogenomics and molecular targets and biomarkers, chemical/drug/molecular toxicology, absorption, distribution, metabolism and elimination (ADME), pharmacokinetics (PK) and pharmacodynamics (PD), Modeling & Simulation (M&S) and pharmacometrics, and other related topics in pharmacology including neurology/central nervous system (CNS), cardiovascular, metabolic diseases, cancer, among others. Section Editors for Current Pharmacology Reports select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided. This journal publishes on a bi-monthly schedule.Please submit here: https://www.editorialmanager.com/phar/default.aspx
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
